<DOC>
	<DOCNO>NCT02169583</DOCNO>
	<brief_summary>This first time GSK1325756 Solution Infusion formulation administer human . Prior study perform oral GSK1325756 . The primary objective study obtain information safety , tolerability , pharmacokinetics ( PK ) single twice daily intravenous ( IV ) administration GSK1325756 healthy subject . In Part A , single , escalate dos give cohort subject seven day washout . In addition , study evaluate absolute bioavailability single dose current oral tablet formulation compare IV formulation Part A . In Part B , twice daily ( BID ) intravenous dose administration give 5 day ( 9 total dos ) two separate cohort subject . Data study provide understand safety , tolerability , PK intravenously administer GSK1325756 twice daily guide dose selection future clinical study patient viral respiratory tract infection</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Single Repeat Escalating Doses GSK1325756 Solution Infusion , Absolute Bioavailability Relative Oral Dose , Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males/females age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include ( medical history , physical examination , laboratory test ECG ) . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure Body weight &gt; =60 kilogram ( kg ) men &gt; =45 kg woman ; Body Mass Index ( BMI ) within range 19 32 kg/square meter ( m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit ( MIU ) /milliliter ( mL ) estradiol &lt; 40 picograms ( pg ) /mL ( &lt; 147 picomoles [ pmol ] /liter [ L ] ) confirmatory ] . Male subject female partner childbearing potential must agree use one acceptable contraception method . This criterion must follow time first dose study medication 90 day follow last dose . Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single ECG obtain brief recording period : correct QT interval ( QTc ) &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block . Capable give write informed consent , include compliance requirement restriction list consent form . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GlaxoSmithKline ( GSK ) Medical Monitor , contraindicate participation . Part A : Subjects currently likely take antacid ( H2 receptor antagonist , proton pump inhibitor [ PPI ] blocker , etc . ) point study . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Pregnant female determine positive ( serum urine ) human chorionic gonadotropin ( hCG ) test screen prior dosing . Subjects peripheral blood neutrophil count screen visit &lt; 2 x 10^9/L . Subjects history renal disease subject abnormal urinalysis ( confirmed repeat ) suggest possibility renal disease ( e.g . proteinuria ) . Subjects serum creatinine screen visit &gt; 1 x ULN . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK1325756</keyword>
	<keyword>Safety</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>